Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
- 08 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.